CN101873857A - 用于治疗亨廷顿舞蹈病和多系统萎缩的mpo抑制剂 - Google Patents

用于治疗亨廷顿舞蹈病和多系统萎缩的mpo抑制剂 Download PDF

Info

Publication number
CN101873857A
CN101873857A CN200880111701A CN200880111701A CN101873857A CN 101873857 A CN101873857 A CN 101873857A CN 200880111701 A CN200880111701 A CN 200880111701A CN 200880111701 A CN200880111701 A CN 200880111701A CN 101873857 A CN101873857 A CN 101873857A
Authority
CN
China
Prior art keywords
tetrahydrochysene
sulfo
methyl
purine
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880111701A
Other languages
English (en)
Chinese (zh)
Inventor
哈坎·埃里克森
沃纳·波维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to CN202110874748.4A priority Critical patent/CN113633641A/zh
Priority to CN201610055826.7A priority patent/CN105687199A/zh
Publication of CN101873857A publication Critical patent/CN101873857A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN200880111701A 2007-08-23 2008-08-22 用于治疗亨廷顿舞蹈病和多系统萎缩的mpo抑制剂 Pending CN101873857A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202110874748.4A CN113633641A (zh) 2007-08-23 2008-08-22 用于治疗亨廷顿舞蹈病和多系统萎缩的mpo抑制剂
CN201610055826.7A CN105687199A (zh) 2007-08-23 2008-08-22 用于治疗亨廷顿舞蹈病和多系统萎缩的mpo抑制剂

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95752507P 2007-08-23 2007-08-23
US95752307P 2007-08-23 2007-08-23
US60/957,523 2007-08-23
US60/957,525 2007-08-23
PCT/SE2008/050950 WO2009025618A1 (en) 2007-08-23 2008-08-22 Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN202110874748.4A Division CN113633641A (zh) 2007-08-23 2008-08-22 用于治疗亨廷顿舞蹈病和多系统萎缩的mpo抑制剂
CN201610055826.7A Division CN105687199A (zh) 2007-08-23 2008-08-22 用于治疗亨廷顿舞蹈病和多系统萎缩的mpo抑制剂
CN201310681047.4A Division CN103638029A (zh) 2007-08-23 2008-08-22 用于治疗亨廷顿舞蹈病和多系统萎缩的mpo抑制剂

Publications (1)

Publication Number Publication Date
CN101873857A true CN101873857A (zh) 2010-10-27

Family

ID=40378392

Family Applications (4)

Application Number Title Priority Date Filing Date
CN200880111701A Pending CN101873857A (zh) 2007-08-23 2008-08-22 用于治疗亨廷顿舞蹈病和多系统萎缩的mpo抑制剂
CN201310681047.4A Pending CN103638029A (zh) 2007-08-23 2008-08-22 用于治疗亨廷顿舞蹈病和多系统萎缩的mpo抑制剂
CN201610055826.7A Pending CN105687199A (zh) 2007-08-23 2008-08-22 用于治疗亨廷顿舞蹈病和多系统萎缩的mpo抑制剂
CN202110874748.4A Pending CN113633641A (zh) 2007-08-23 2008-08-22 用于治疗亨廷顿舞蹈病和多系统萎缩的mpo抑制剂

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201310681047.4A Pending CN103638029A (zh) 2007-08-23 2008-08-22 用于治疗亨廷顿舞蹈病和多系统萎缩的mpo抑制剂
CN201610055826.7A Pending CN105687199A (zh) 2007-08-23 2008-08-22 用于治疗亨廷顿舞蹈病和多系统萎缩的mpo抑制剂
CN202110874748.4A Pending CN113633641A (zh) 2007-08-23 2008-08-22 用于治疗亨廷顿舞蹈病和多系统萎缩的mpo抑制剂

Country Status (25)

Country Link
US (6) US20090054468A1 (enExample)
EP (1) EP2200616B1 (enExample)
JP (2) JP5247804B2 (enExample)
KR (1) KR101588464B1 (enExample)
CN (4) CN101873857A (enExample)
AU (1) AU2008289653B2 (enExample)
BR (1) BRPI0815681A2 (enExample)
CA (1) CA2698205C (enExample)
CY (1) CY1113714T1 (enExample)
DK (1) DK2200616T3 (enExample)
EA (1) EA017510B1 (enExample)
ES (1) ES2399846T3 (enExample)
HR (1) HRP20130139T1 (enExample)
IL (2) IL203738A (enExample)
ME (1) ME01510B (enExample)
MX (1) MX2010001983A (enExample)
MY (1) MY155633A (enExample)
NZ (1) NZ584135A (enExample)
PH (1) PH12014501180A1 (enExample)
PL (1) PL2200616T3 (enExample)
PT (1) PT2200616E (enExample)
RS (1) RS52665B (enExample)
SI (1) SI2200616T1 (enExample)
WO (1) WO2009025618A1 (enExample)
ZA (1) ZA201000848B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111182898A (zh) * 2017-06-28 2020-05-19 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CN114945573A (zh) * 2019-10-10 2022-08-26 拜奥海芬治疗学有限公司 髓过氧化物酶抑制剂的前药
WO2024120457A1 (zh) * 2022-12-09 2024-06-13 深圳信立泰药业股份有限公司 一种吡咯并[3,2-d]嘧啶-4-酮类衍生物及其制备方法和医药用途
CN121378265A (zh) * 2025-10-30 2026-01-23 乐平市康鑫医药化工有限公司 一种吡唑类化合物及其制备方法和用途

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
UY30267A1 (es) * 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
US8927559B2 (en) 2010-10-11 2015-01-06 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as CRTH2 antagonists
GEP201706656B (en) 2011-11-11 2017-04-25 Pfizer 2-thiopyrimidinones
WO2013144088A1 (en) * 2012-03-29 2013-10-03 Basf Se N-substituted hetero-bicyclic compounds and derivatives for combating animal pests ii
US9616063B2 (en) * 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
MA42035A (fr) 2015-05-05 2018-03-14 Pfizer 2-thiopyrimidinones
CA3068910A1 (en) * 2017-07-17 2019-01-24 Astrazeneca Ab Mpo inhibitors for use in medicine
MX2022010902A (es) * 2020-03-05 2022-10-07 Biohaven Therapeutics Ltd Metodo para tratar la esclerosis lateral amiotrofica con un inhibidor de la mieloperoxidasa.
EP4146219A4 (en) * 2020-05-06 2024-05-22 Biohaven Therapeutics Ltd. PROCESS FOR PREPARING VERDIPERSTAT
CN115403584B (zh) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用
UY40399A (es) 2022-08-18 2024-02-15 Astrazeneca Ab Inhibidores de mieloperoxidasa
AU2023332020A1 (en) * 2022-08-31 2025-04-17 Astrazeneca Ab Pharmaceutical formulation
WO2024163892A1 (en) * 2023-02-02 2024-08-08 University Of Virginia Patent Foundation Myeloperoxidase (mpo) inhibition as a treatment target for delayed cerebral injury (dci) in aneurysmal subarachnoid hemorrhage (sah)
WO2025172474A1 (en) 2024-02-15 2025-08-21 Astrazeneca Ab Inhibitors of myeloperoxidase
WO2025190901A1 (en) 2024-03-13 2025-09-18 Institut National de la Santé et de la Recherche Médicale Use of myeloperoxidase (mpo) inhibitors for promoting cd8+ t cell responses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69834500T2 (de) * 1997-09-05 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. Xanthinderivative zur behandlung von hirnischämie
GB0100620D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
ES2686123T3 (es) * 2002-01-28 2018-10-16 Kyowa Hakko Kogyo Co., Ltd Antagonistas del receptor A2A para su uso en el tratamiento de trastornos del movimiento
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
UY30267A1 (es) * 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
WO2007142577A1 (en) * 2006-06-05 2007-12-13 Astrazeneca Ab Pyrrolo[3,2-d]pyrimidin-4-one derivative as myeloperoxidase inhibitor
AR066936A1 (es) * 2007-06-13 2009-09-23 Astrazeneca Ab 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas.
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111182898A (zh) * 2017-06-28 2020-05-19 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CN111182898B (zh) * 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CN114945573A (zh) * 2019-10-10 2022-08-26 拜奥海芬治疗学有限公司 髓过氧化物酶抑制剂的前药
WO2024120457A1 (zh) * 2022-12-09 2024-06-13 深圳信立泰药业股份有限公司 一种吡咯并[3,2-d]嘧啶-4-酮类衍生物及其制备方法和医药用途
CN121378265A (zh) * 2025-10-30 2026-01-23 乐平市康鑫医药化工有限公司 一种吡唑类化合物及其制备方法和用途

Also Published As

Publication number Publication date
JP5247804B2 (ja) 2013-07-24
CN105687199A (zh) 2016-06-22
CA2698205C (en) 2016-06-21
PL2200616T3 (pl) 2013-04-30
US10772890B2 (en) 2020-09-15
EA201000202A1 (ru) 2010-10-29
US20090054468A1 (en) 2009-02-26
US20140221400A1 (en) 2014-08-07
WO2009025618A1 (en) 2009-02-26
IL203738A (en) 2015-08-31
JP2010536849A (ja) 2010-12-02
JP2013151547A (ja) 2013-08-08
KR101588464B1 (ko) 2016-01-25
IL240130A0 (en) 2015-09-24
CY1113714T1 (el) 2016-06-22
US20190099423A1 (en) 2019-04-04
ME01510B (me) 2014-04-20
CA2698205A1 (en) 2009-02-26
US20110207755A1 (en) 2011-08-25
ZA201000848B (en) 2012-07-25
AU2008289653B2 (en) 2012-06-28
NZ584135A (en) 2012-04-27
BRPI0815681A2 (pt) 2015-02-18
EP2200616A4 (en) 2010-08-25
SI2200616T1 (sl) 2013-03-29
MX2010001983A (es) 2010-03-10
KR20100055434A (ko) 2010-05-26
CN113633641A (zh) 2021-11-12
US20200405724A1 (en) 2020-12-31
HK1145141A1 (en) 2011-04-08
ES2399846T3 (es) 2013-04-03
US20130059870A1 (en) 2013-03-07
EA017510B1 (ru) 2013-01-30
AU2008289653A1 (en) 2009-02-26
PT2200616E (pt) 2013-02-27
EP2200616B1 (en) 2012-12-26
EP2200616A1 (en) 2010-06-30
MY155633A (en) 2015-11-13
RS52665B (sr) 2013-06-28
PH12014501180A1 (en) 2015-08-24
HRP20130139T1 (hr) 2013-03-31
CN103638029A (zh) 2014-03-19
DK2200616T3 (da) 2013-03-04

Similar Documents

Publication Publication Date Title
US10772890B2 (en) Use of myeloperoxidase (MPO) inhibitors or pharmaceutically acceptable salts thereof to treat multiple system atrophy (MSA) 938
Dal Piaz et al. Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies
JP6270907B2 (ja) 嚢胞性線維症処置用のｓＧＣ刺激剤又はｓＧＣ活性化剤単独及びＰＤＥ５阻害剤との組み合わせ物
JP5997182B2 (ja) 嚢胞性線維症の処置のための新規組成物
US20080021013A1 (en) JAK inhibitors for treatment of myeloproliferative disorders
CN1426310A (zh) 促进排便的药物组合物
US20210379061A1 (en) Balipodect for treating or preventing autism spectrum disorders
WO2020233706A1 (zh) 一种治疗躁狂型精神障碍及精神分裂症的药物
EP1638559A1 (fr) Utilisation de pyrazolopyridines pour le traitement de deficits cognitifs
HK1145141B (en) Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy
RU2776109C1 (ru) Лекарственный препарат для лечения хронического кашля
CN120346202A (zh) Ripk1抑制剂及其在治疗神经功能障碍中的用途
KR20010040671A (ko) 소뇌 기능장애 예방 또는 치료를 위한2-아미노-6-트리플루오로메톡시-벤조티아졸의 용도
US20110046141A1 (en) Use of pde5 inhibitors for treating circadian rhythm disorders
NZ613118B2 (en) Novel composition for the treatment of cystic fibrosis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20101027